View Featured Offers >>
12579
Human His6IGFBP3 (hHis6IGFBP3)
Cytokines & Growth Factors
Growth Factors and Cytokines

Human His6IGFBP3 (hHis6IGFBP3) #12579

Citations (0)
The inhibition of IGF-I induced Akt phosphorylation by hHis6IGFBP3. Human dermal fibroblasts were treated with Human Insulin-like Growth Factor I (hIGF-I) # 8917 in the presence or absence of increasing concentrations of hHis6IGFBP3 for 10 minutes, lysed, and Akt1 (Ser473) phosphorylation was quantified using the PathScan® Phospho-Akt1 (Ser473) Sandwich ELISA Kit #7160.
The purity of recombinant hHis6 IGFBP3 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant

hHis6 IGFBP3 and staining overnight with Coomassie Blue.

Storage

Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Product Description

MW (kDa) 50
Purity >95% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant hHisIGFBP3. All lots are greater than 95% pure.
Endotoxin Less than 0.01 ng endotoxin/1 μg hHis6IGFBP3.
Activity The bioactivity of hHis6IGFBP3 was determined by inhibition of IGF-I induced AKT phosphorylation in human dermal fibroblasts. The ED50 of each lot is between 2.5-9 ng/ml.
Molecular Formula Recombinant N-terminally His6-tagged hIGFBP3 has a calculated MW of 30,7123 Da. DTT reduced and nonreduced protein migrate as 50 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant hHis6IGFBP3 was verified by amino acid sequencing.

Source / Purification

Recombinant Human His6IGFBP3 (hHis6IGFBP3) Gly28-Lys291 (Accession #NP_17936) was expressed in human 293 cells at Cell Signaling Technology.

Background

IGFBP3 is a multifunctional protein that plays a key role in regulation of IGFI/II activity, cell proliferation, and death. One of six high-affinity IGF binding proteins, IGFBP3 is the major species in circulation and is bound in a complex with ALS to 99% of hepatic IGF-I (1). Proteolytic degradation of IGFBP3 increases the bioavailability and activity of the IGF I/II (1). However, some biological activities of IGFBP3 are independent of the IGF/IGF-IR axis. IGFBP3 potentiates EGF-induced breast cancer cell proliferation in vitro by enhancing ERK phosphorylation and sphingosine kinase-mediated EGFR trans-activation (2,3). Conversely, IGFBP3 has been shown to induce apoptosis and inhibit NF-κB activity (4).

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

For Research Use Only. Not for Use in Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PathScan is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.
Inquiry Info.# 12579